Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

  • Technology appraisal guidance
  • TA832
  • Published: 

Register as a stakeholder

History

Documents created during the development process.

Expected publication

Appeal

Final draft guidance

Invitation to participate

Scoping workshop: Manchester